KING OF PRUSSIA, Pa., Jan. 3, 2012 /PRNewswire/ -- CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for self-administration of Berinert(®), C1 Esterase Inhibitor (Human), a pasteurized, nanofiltered therapy indicated for the treatment of acute attacks ... read more

KING OF PRUSSIA, Pa., Dec. 2, 2011 /PRNewswire/ -- CSL Behring announced today that it has awarded a $40,000 advocacy grant to the American Plasma Users Coalition (A-PLUS) through its Local Empowerment for Advocacy Development (LEAD) program. LEAD grants support the grassroots advocacy efforts of organizations that help people who ... read more

BOSTON, Nov. 5, 2011 /PRNewswire/ -- New findings demonstrate that treatment with C1-esterase inhibitor (C1-INH) concentrate is effective in treating acute swelling attacks in children and adolescents with type I or type II hereditary angioedema (HAE), a rare and serious genetic disorder. Study results show that the outcomes of treatment ... read more

BOSTON, Nov. 5, 2011 /PRNewswire/ -- C1-esterase inhibitor (C1-INH) concentrate at 20 U/kg is a safe and effective therapy for the long-term treatment of successive acute swelling attacks at any body location in patients with hereditary angioedema (HAE), a rare and serious genetic disorder, according to final data presented at ... read more

KING OF PRUSSIA, Pa., Oct. 6, 2011 /PRNewswire/ -- CSL Behring, a global biotherapeutics company specializing in plasma-derived and recombinant therapies that does business in 27 countries, has been named Life Sciences Company of the Year by Philadelphia Business Journal and Pennsylvania Bio. The King of Prussia-based business is ... read more

"Raise Your Voice!" teaches them to be their own best advocate, particularly in tough budget times when legislation and policy decisions could affect their access to care. KING OF PRUSSIA, Pa., Oct. 3, 2011 /PRNewswire-USNewswire/ -- Young people between the ages of 15 and 22 converged on Washington, D.C. this summer, ... read more

KING OF PRUSSIA, Pa., Sept. 6, 2011 /PRNewswire/ -- To demonstrate its continued commitment to innovative immunoglobulin (Ig) research, CSL Behring announced today it is seeking proposals for the next round of Interlaken Leadership Awards. Established in 2010, this annual global awards program provides monetary grants and/or product supply ... read more

MISSION, KS -- (Marketwire) -- 10/25/10 -- (Family Features) Imagine living in a world where even common germs can trigger extreme illness that won't go away. This is the reality for nearly 10 million children and adults living with primary immunodeficiency (PI). PI encompasses a group of disorders, ... read more